Assembly Biosciences (ASMB) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a sell rating to a hold rating in a research report report published on Tuesday, BidAskClub reports.

Several other brokerages have also recently weighed in on ASMB. Zacks Investment Research upgraded Assembly Biosciences from a hold rating to a buy rating and set a $24.00 target price for the company in a report on Thursday, February 21st. Chardan Capital restated a hold rating and set a $30.00 target price on shares of Assembly Biosciences in a report on Monday, April 15th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $43.00.

ASMB stock traded down $0.65 during trading on Tuesday, hitting $15.17. 825 shares of the company traded hands, compared to its average volume of 276,400. The stock has a market capitalization of $404.20 million, a PE ratio of -3.77 and a beta of 1.60. Assembly Biosciences has a 1 year low of $13.13 and a 1 year high of $48.91. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.97 and a quick ratio of 12.05.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.01. The company had revenue of $3.89 million during the quarter, compared to analysts’ expectations of $3.81 million. Assembly Biosciences had a negative return on equity of 56.45% and a negative net margin of 671.48%. Analysts anticipate that Assembly Biosciences will post -4.34 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA raised its position in Assembly Biosciences by 87,340.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,372 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 4,367 shares during the last quarter. Legal & General Group Plc raised its position in Assembly Biosciences by 17.0% during the 4th quarter. Legal & General Group Plc now owns 3,847 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 558 shares during the last quarter. Marshall Wace North America L.P. raised its position in Assembly Biosciences by 191.5% during the 1st quarter. Marshall Wace North America L.P. now owns 4,431 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 2,911 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in Assembly Biosciences by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,073 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 5,524 shares during the last quarter. Finally, Blair William & Co. IL raised its position in Assembly Biosciences by 18.5% during the 1st quarter. Blair William & Co. IL now owns 10,825 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 1,687 shares during the last quarter. 84.34% of the stock is owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

See Also: Net Income

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.